Vesugen calculator
A short blood-vessel-targeted 'peptide bioregulator' marketed for vascular support. Evidence is thin and largely regional.
Also known as: Vascular peptide bioregulator, Lys-Glu-Asp tripeptide
FDA status — not an approved drug Not FDA-approved for any use. Vesugen is a peptide bioregulator sold as a research or supplement product and is not reviewed by FDA.
Schedule Vesugen → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Vesugen is
Vesugen is a short peptide marketed as a vascular 'bioregulator,' part of the cytomedin class developed in Russia. It is claimed to support the function of blood-vessel endothelial cells. It is not approved in the United States and lacks rigorous, independently replicated clinical evidence.
Research depth: 1/5 Limited regional research; no large randomized or Western trials. Human trials: None published in major journals. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Vesugen works
Like other cytomedin bioregulators, it is claimed to enter cells and regulate gene expression in a tissue-specific manner — here, in the vascular endothelium. This mechanism is not established by rigorous Western research.
Vesugen side effects
Commonly reported
- Generally reported as well tolerated in regional literature
- No robust Western safety data
Serious — seek medical care
- Evidence base is thin and not independently replicated
- Quality and purity vary widely among suppliers
- Not a substitute for evidence-based cardiovascular care
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 20 mg vial reconstituted with 1 mL of bacteriostatic water gives 20 mg/mL. A 20000 mcg dose is then 1 mL — about 100 units on a 100-unit insulin syringe, giving roughly 1 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Vesugen dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Vesugen run from 10000 mcg to 30000 mcg. Bioregulator peptides are typically sold as oral capsules dosed in milligrams. Figures shown are community reference amounts in micrograms. There is no established or approved dose.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Vesugen at all are decisions for a licensed clinician who knows your history.
Common questions
Is Vesugen proven to help blood vessels?
No robust, independently replicated clinical evidence supports it. It is a regional bioregulator product with limited data.
What is a bioregulator peptide?
A class of short peptides developed mainly in Russia, claimed to normalize organ-specific cell function. The claims rest largely on regional research not reproduced in large Western trials.